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Introduction: Diabetes mellitus (DM) is associated with increased risk of hospitalisation in 
people with heart failure and reduced ejection fraction (HFrEF). However, little is known 
about the causes of these events. 
 
Methods: Prospective cohort study of 711 people with stable HFrEF. Hospitalisations were 
categorised by cause as: decompensated heart failure; other cardiovascular; infection; or 
other non-cardiovascular. Rates of hospitalisation and burden of hospitalisation (percentage 
of follow-up time in hospital) were compared in people with and without DM. 
 
Results: After a mean follow-up of 4.0 years, 1568 hospitalisations occurred in the entire 
cohort. DM (present in 32% [n=224]) was associated with a higher rate (mean 1.07 vs. 0.78 
per 100 patient-years; p<0.001) and burden (3.4 vs. 2.2% of follow-up time; p<0.001) of 
hospitalisation. Cause-specific analyses revealed increased rate and burden of hospitalisation 
due to decompensated heart failure, other cardiovascular causes and infection in people with 
DM, whereas other non-cardiovascular causes were comparable. Infection made the largest 
contribution to the burden of hospitalisation in people with and without DM. 
 
Conclusions: In people with HFrEF, DM is associated with a greater burden of hospitalisation 
due to decompensated heart failure, other cardiovascular events and infection, with infection 
making the largest contribution.  
 




Heart failure with reduced left ventricular ejection fraction (HFrEF) affects tens of millions of 
people across the world;(1) it is associated with both reduced life expectancy and impaired 
quality of life.(2,3) Furthermore, it has a substantial impact on individuals and health care 
systems due to the frequent occurrence of hospitalisation events. Heart failure (HF) is usually 
part of a broader syndrome of multimorbidity,(4) with diabetes mellitus (DM) being common, 
affecting 15-41% of people with HFrEF.(5) The combination of DM and HFrEF is clinically 
important because of the increased risk of death,(6) greater loss of life expectancy,(3) and 
more frequent hospitalisation,(7–9) despite contemporary HF therapy. Prevention of 
hospitalisation is therefore one of the major goals to improve care and reduce healthcare 
costs in this population,(10)  yet little is known about the causes of hospitalisation events and 
their overall burden. Therefore, we set out to comprehensively characterise the causes and 
overall burden of hospitalisation episodes in a cohort with HFrEF, and then define the impact 
of comorbid DM on these phenomena. 
 
Methods  
As we have previously described,(11,12) we conducted a prospective observational cohort 
study to explore outcomes and define prognostic markers in patients with HFrEF. The cohort 
consists of 3 discretely recruited subgroups and this analysis is restricted to the most recently 
recruited group of 711 people, in whom detailed hospitalisation data are available.(13) 
Inclusion in the study required the presence of stable signs and symptoms of CHF for at least 
3 months, age ≥18 years, and LVEF ≤45% on transthoracic echocardiography. Between 
February 2012 and December 2014, all patients meeting these criteria and attending 
specialist cardiology clinics (secondary and tertiary referral) in 4 UK hospitals were 
approached; all those who agreed to participate provided written informed consent. 
Participants received routine contemporary evidence-based care, guided by the supervising 
clinical team, with no study intervention; they were then observed until censorship or death, 
as described below. The Leeds West Research Ethics Committee gave ethical approval 
(07/Q1205/17), and the investigation conformed to the principles outlined in the Declaration 
of Helsinki.  
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Patient baseline characteristics including demographics, past medical history, functional 
capacity (according to the New York Heart Association classification), electrocardiography 
(ECG), laboratory blood tests, cardiac imaging, and treatment were collected at enrolment. 
Diabetes was defined using past medical history and medication data at baseline. Two-
dimensional echocardiography was performed according to The American Society of 
Echocardiography recommendations. Resting heart rate was measured using 12-lead ECG. 
Prescribed doses of loop diuretics, angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARB), and beta-blockers were collected at study recruitment. 
Total daily doses of beta-blocker, ACE inhibitors (or ARB if used instead of ACE inhibitors), and 
loop diuretic were expressed relative to the maximal licensed dose of bisoprolol, ramipril, and 
furosemide, respectively, as previously published.(11) Receipt of cardiac resynchronisation 
therapy (CRT) and implantable cardioverter-defibrillator (ICD) implantation was assessed 
during the 6-month period after recruitment.  
 
Assessment of outcomes: All patients were registered with the UK Office of Population 
Censuses and Surveys, which provided details of time of death, with a final censorship date 
of February 18, 2019. Hospitalisation data were collected from institutional clinical event 
databases detailing all admissions in recruiting centres. All non-elective hospital admissions 
experienced before death or study censorship were included, and characterised by 2 
investigators according to their time from study recruitment, duration, and primary cause 
within four major categories: 1) HF hospitalisation; 2) Other cardiovascular hospitalisation 
(e.g. arrhythmia or acute coronary syndrome, without decompensated HF); 3) Infection-
related hospitalisation; 4) Other non-cardiovascular hospitalisation (non-cardiovascular cause 
excluding infection-related). HF hospitalisation was defined as new onset or worsening of 
signs and symptoms of heart failure with evidence of fluid overload requiring at least 24 hours 
hospitalisation and the use of intravenous diuretics, as we have previously published.(7) 
Infection-related hospitalisation was defined as infection being the primary reason for 
hospitalisation with documented source (or suspected source), accompanied by deteriorating 
symptoms, signs (e.g., pyrexia, tachycardia, hypotension, tachypnoea, confusion) and 
laboratory indices (e.g. elevated inflammatory markers, with microbiological, serological, 
and/or imaging evidence) resulting in treatment with antimicrobial therapy, as we have 
previously published;(13) infection source was also categorised as previously described.(13) 
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Statistics: All statistical analyses were performed using IBM SPSS statistics version 27 (IBM 
Corporation, Armonk, NY). Categorical data are shown as number (percentage). Continuous 
descriptive data are presented as mean (standard error of the mean) after confirming 
normality of distribution. Since hospitalisation metrics were highly skewed and often included 
zero-value median and quartile values, we do not present these indices and instead illustrate 
distributions across percentiles, along with mean data to illustrate group-level data (which 
are important to consider whole population outcomes, but should not be used to consider 
individual-level outcomes). Groups were compared using Student t-tests for normally 
distributed continuous data, Mann-Whitney U-tests for non-normally distributed continuous 
data, and Pearson Chi-squared tests for categorical data. Participant-level hospitalisation 
burden was expressed as a percentage of the time in follow-up before death or censorship to 
account for differing survival between groups and was compared using Mann-Whitney U-
tests. The participant-level rate of hospitalisation was calculated as the number of 
hospitalisation episodes during follow-up divided by the duration of follow-up in years and 
was compared using Mann-Whitney U-tests. All tests were 2-sided, and statistical significance 




Of the 711 study participants, 224 (32%) had DM and their characteristics versus those 
without DM are presented in Table 1. People with DM has similar left ventricular ejection 
fraction to those without DM, but had lower functional capacity measured by the New York 
Heart Association classification; the aetiology of HF was more commonly ischaemic in people 
with DM. Estimated glomerular filtration rate and haemoglobin were lower in people DM, 
and they received higher doses of ACE inhibitor and loop diuretic. Rates of ICD implantation 
were low in both groups, probably reflecting a requirement for full medication optimisation 
and updated cardiac imaging prior to making device implantation recommendations.  Socio-
economic deprivation, as calculated by the Index of Multiple Deprivation, was also higher in 
people with DM. Within the DM group, mean HbA1c was 61 (SEM 1) mmol/mol, 31 people 
(13.8%) received insulin as part of their diabetes therapy and 78 (34.8%) people managed 




After a mean follow-up period of 4.0 years (4.1 for people without DM vs. 3.9 for people with 
DM; Mann-Whitney p=0.33), equating to 2879 participant-years of follow-up, 467 (66%) 
people were hospitalised at least once and a total of 1568 hospitalisation events occurred. 
People with DM had significantly higher rates of hospital admission than those without DM 
(mean 1.07/year vs. 0.78/year; median 0.52/year vs. 0.27/year; p<0.001; Figure 1). Cause-
specific analyses showed significantly higher rates of hospitalisation due to decompensated 
heart failure (mean 0.17/year vs. 0.12/year; p=0.003; Figure 2A), other cardiovascular events 
(mean 0.18/year vs. 0.12/year; p=0.043; Figure 2B), and infections (mean 0.39/year vs. 
0.23/year; p=0.003; Figure 2C) in people with DM, although rates of other non-cardiovascular 
hospitalisation were similar to those without DM (mean 0.34/year vs. 0.31/year; p=0.44; 
Figure 2D). Of the 204 and 261 infection hospitalisations in people with and without DM, 
respectively, we noted significant differences in the source of infection (Chi-squared p<0.001), 
with a smaller proportion of respiratory tract and a larger proportion of soft tissue infection 
in the DM group (Table 2). 
 
Hospitalisation burden 
The total burden of hospitalisation, expressed as percentage of lifetime in hospital during 
follow-up, was much greater in people with DM than without DM (mean 3.4% vs. 2.2%; 
median 1.1% vs. 0.3%; p<0.001; Figure 3); this represents a mean of 32.0 and 18.8 days in 
hospital for people with and without DM, respectively. Again, cause-specific analyses showed 
significantly higher burden of hospitalisation due to decompensated heart failure (mean 0.5% 
vs. 0.3%; p=0.002; Figure 4A), other cardiovascular events (mean 0.6% vs. 0.2%; p=0.021; 
Figure 4B), and infections (mean 1.6% vs. 1%; p=0.005; Figure 4C), but not other non-
cardiovascular events (mean 0.7% vs. 0.7%; p=0.46; Figure 4D). Notably, infection made the 
largest contribution to the burden of hospitalisation in people with and without DM (46.3% 
and 43.6%), followed by other non-cardiovascular events (21.3% and 33.4%), decompensated 






Our detailed analysis of all hospitalisation events experienced by 711 people with HFrEF over 
a 4-year period has revealed a number of important findings. First, DM is associated with a 
38% higher rate of hospitalisation and an even larger proportional increase (54%) in the 
overall time people spend in hospital. Second, the increase in hospitalisation of people with 
DM is due to decompensated HF, other-cardiovascular and infection events, but not other 
non-cardiovascular events. Finally, infection events account for almost half of the time people 
with HFrEF and DM spend in hospital, which is much larger than any other major category of 
hospitalisation, including decompensated heart failure. Notably, the proportion of respiratory 
tract infections was lower, and the proportion of soft tissue infections higher, in people with 
DM versus without DM. These observations have many implications for clinical practice and 
research, as we discuss below. 
 
It is well established that DM is a risk factor for hospitalisation in people with HFrEF.(5) For 
example, the CHARM investigators found that diabetes was associated with a 2.04-fold 
adjusted risk of decompensated heart failure hospitalisation in people with HFrEF using data 
describing only first hospitalisations during follow-up.(14) Notably, they found that fewer 
than 10% of hospitalisations were attributable to decompensated HF in people with DM, 
broadly in keeping with our data. Indeed, even in the recent EMPEROR-Reduced trial of 
Empagliflozin in HFrEF, which specifically recruited people at high risk of worsening HF, fewer 
than one third all hospitalisations during follow up were attributed to decompensated HF.(15) 
Collectively, these data show that other causes of hospitalisation (beyond decompensated 
heart failure) are an important target to reduce the personal and economic burden of 
hospitalisation in people with HFrEF plus DM. Currently, these other causes of hospitalisation 
are neglected in our focus to improve outcomes of people with HF. Our data suggest that 
infection hospitalisation is a particularly important target, since it accounted for almost half 
of hospitalised time.  
 
We have recently shown that many non-communicable diseases, including DM and chronic 
cardiac disease, are risk factors for fatal infection.(16) Notably, we found that the 
accumulation of multimorbidity is associated with greater increases in the relative risk of 
infection than non-infection death. Hence, it is not unexpected that the added morbidity of 
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DM in people with HFrEF is associated with greater risk of adverse infection outcomes. 
Furthermore, recent data from the PARADIGM trial of sacubutril/valsartan in HFrEF showed 
that people developing pneumonia, the commonest cause of infection hospitalisation in this 
population,(13) were more likely to have DM.(17) Indeed, respiratory tract infection was the 
single largest cause of infection hospitalisation in both people with and without DM in our 
analysis above (Table 2). In order to reduce the risk of infection, vaccination against common 
pathogens is one potentially useful strategy,(18) and we know that uptake of influenza 
vaccine is suboptimal in people with HF.(19) Hence, efforts should be made to encourage 
vaccination in people with HFrEF and DM. However, much more work is also needed to 
understand how this group is predisposed to infection so that we can develop improved 
strategies to prevent adverse infection outcomes. For example, our analysis suggests that 
understanding how to prevent or mitigate the progression of soft tissue infection may be 
particularly important for people with DM and HFrEF. Beyond infection hospitalisation, it is 
also important to emphasise that other non-cardiovascular events made a large contribution 
to hospitalisation in people with DM, as did other cardiovascular events (beyond 
decompensated HF). This highlights the need for holistic approaches to prevent 
hospitalisation, which would ideally be personalised based on individual risk factors for 
specific causes of hospitalisation. 
 
Beyond the 38% higher mean rate of hospitalisation in our population with HFrEF and DM, 
the mean burden of hospitalisation was 54% higher, indicating that the length of stay per 
hospitalisation was also greater. This is supported by the wider literature. For example, the 
OPTIMIZE-HF registry of 48,612 patients with HFrEF reported a modestly increased length of 
stay in people with DM (5.9 vs 5.5 days for non-diabetic patients).(9) Similarly, the larger 
GWTG-HF registry also reported a 14% greater adjusted odds of hospitalisation longer than 4 
days in people with heart failure and comorbid DM.(8) These data highlight the need to 
identify modifiable factors associated with DM that prolong hospitalisation, which could 
inform strategies to reduce the personal and economic burden of individual hospitalisation 
episodes. Notably, our figures illustrate that a minority of people account for the majority of 




Beyond the described strength of our work, it is also important to acknowledge some 
limitations. First, we have no data regarding people with heart failure and preserved ejection 
fraction (HFpEF), which represents around half of all cases of heart failure.(20) This is relevant 
because data from the previously described analysis of the CHARM programme found that 
DM was associated with a greater relative risk of decompensated heart failure hospitalisation 
in HFpEF than HFrEF.(14) Second, we have no data on influenza or pneumococcus vaccination 
rates in our cohort so cannot comment on whether lower uptake of these in people with DM 
could underpin increased risk of infection hospitalisation. Finally, our observations may not 
be generalisable to other HFrEF populations, for example beyond the United Kingdom; 
however, it is reassuring that other studies partly addressing the focus of our analysis have 
reached similar conclusions, as described above. 
 
In conclusion, people with DM and HFrEF experience increased rates of hospitalisation and 
proportionally larger increases in the amount of time spent in hospital. These factors are 
accounted for by increased hospitalisation due to decompensated heart failure, other 
cardiovascular events and infections, with infection accounting for almost half of their time 
in hospital. Strategies to reduce the personal and economic burden of hospitalisation in 
people with HFrEF and DM are likely to require a holistic and personalised approach. 
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Table 1: Participant characteristics 
 Diabetes 
(n = 224) 
No diabetes 
(n = 487) 
p value 
Male % (n)  75.0 (168) 71.5 (348) 0.325 
COPD % (n) 16.5 (37) 16.2 (79) 0.921 
ICD recipient % (n)  8.9 (20) 7.6 (37) 0.544 
Ischaemic Aetiology % (n)   63.8 (142) 48.5 (236) <0.001 
CRT recipient % (n)  21.9 (49) 19.1 (93) 0.389 
NYHA class % (n) 
          I  
          II  
          III  












Age (years) 71.6 (0.7) 71.6 (0.6) 0.949 
eGFR (mL/kg/min) 58.7 (1.6) 63.3 (0.9) 0.013 
LVEF (%)  32.4 (0.6) 31.6 (0.5) 0.439 
Heart Rate (bpm) 77.3 (1.1) 76.7 (0.8) 0.681 
Haemoglobin (g/dL) 12.8 (0.1) 13.5 (0.1) <0.001 
Sodium (mol/L) 139.2 (0.2) 139.8 (0.1) 0.027 
Albumin (g/L) 42.5 (0.2) 42.3 (0.2) 0.474 
Index of Multiple Deprivation  29.7 (1.4) 26.2 (0.9) 0.031 
Ramipril dose (mg/day) 5.4 (0.2) 4.6 (0.2) 0.006 
Bisoprolol dose (mg/day) 4.6 (0.2) 4.2 (0.2) 0.090 
Furosemide dose (mg/day) 67.3 (3.7) 40.3 (1.9) <0.001 
COPD – chronic obstructive pulmonary disease; CRT – cardiac resynchronisation therapy; 
eGFR – estimated glomerular filtration rate; ICD – Implantable cardioverter-defibrillator; LVEF 
– left ventricular ejection fraction; NYHA – New York heart association. 
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Table 2: Sources of infection hospitalisation 
  Diabetes No diabetes 
Respiratory % (n) 43.6 (89) 57.1 (149) 
Soft tissue % (n) 28.4 (58) 16.5 (43) 
Urinary tract % (n) 15.2 (31) 14.6 (38) 
Gastrointestinal % (n) 6.9 (14) 8.8 (23) 
Other or unknown source % (n) 5.9 (12) 3.1 (8) 




Figure 1: Total hospitalisation rates in people with and without DM 
Rates of hospitalisation per year across percentiles of populations with (black squares) or 
without (grey triangles) diabetes mellitus (DM), illustrating the greater rate of hospitalisation 
in people with DM (p<0.001).  
 
Figure 2: Cause-specific hospitalisation rates in people with and without DM 
Rates of cause-specific hospitalisation per year across percentiles of populations with (black 
squares) or without (grey triangles) diabetes mellitus (DM), illustrating the greater rate of 
hospitalisation in people with DM for decompensated heart failure (panel A; p=0.003), other 
cardiovascular events (panel B; p=0.043) and infection (panel C; p=0.003), which was not 
observed for other non-cardiovascular events (panel D; p=0.44). 
 
Figure 3: Total hospitalisation burden in people with and without DM 
Burden of hospitalisation (expressed as percentage of time during follow-up spent in hospital) 
across percentiles of populations with (black squares) or without (grey triangles) diabetes 
mellitus (DM), illustrating the greater rate of hospitalisation in people with DM (p<0.001).  
 
Figure 4: Cause-specific hospitalisation burden in people with and without DM 
Burden of hospitalisation (expressed as percentage of time during follow-up spent in hospital) 
across percentiles of populations with (black squares) or without (grey triangles) diabetes 
mellitus (DM), illustrating the greater rate of hospitalisation in people with DM for 
decompensated heart failure (panel A; p=0.002), other cardiovascular events (panel B; 
p=0.021) and infection (panel C; p=0.005), which was not observed for other non-
cardiovascular events (panel D; p=0.46). 
 
